Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923313 | 0.82 | KDM4E (0.33) | CDK2ALDH1A1RXRARXRBRXRG | |
| SCHEMBL9923309 | 0.82 | CDK2 (0.33) | CDK2 | |
| SCHEMBL9923397 | 0.79 | MAP2K1 (0.39) | LMNAMAP2K1 | |
| SCHEMBL9923089 | 0.75 | MAP2K1 (0.46) | MAP2K1 | |
| SCHEMBL9923090 | 0.73 | JAK1 (0.43) | CDK2KMT2A | |
| SCHEMBL9923050 | 0.72 | JAK1 (0.36) | CDK2TSHRKMT2A | |
| SCHEMBL9923304 | 0.72 | JAK1 (0.36) | CDK2TSHRKMT2A | |
| SCHEMBL9923338 | 0.68 | CDK2 (0.49) | CDK2ALDH1A1LMNATSHRMAP2K1 | |
| SCHEMBL12875621 | 0.68 | CDK2 (0.41) | CDK2TSHRMAP2K1KMT2A | |
| SCHEMBL13751493 | 0.65 | TSHR (0.43) | ALDH1A1LMNATSHRTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | PIK3CA 77/4885PIK3CD 100/4885PIK3CB 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.